Autolus Therapeutics plc

Stage 2 · Advancing · week 11

As of Oct 22, 2026, Autolus Therapeutics is in Stage 2, the uptrend phase, now in week 11 (since Aug 12, 2026). It closed at $1.58, 37.8% below its 52-week high and below its 200-day average, which is rising.

$1.58

-2.47% today

$421M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is AUTL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 19w

S4 30w

S4 15w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 7w → S3 6w → S2 19w → S3 10w → S4 8w → S1 3w → S4 3w → S1 3w → S4 3w → S1 3w → S4 30w → S1 8w → S2 3w → S3 3w → S4 15w → S1 10w → S4 5w → S1 4w → S4 1w → S1 1w → S2 8w → S3 2w → S2 10w current

Total tracked: 165 weeks across 23 stage runs.

AUTL among Biotechnology199th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…199	AUTLAutolus Therapeutics plc	Stage 2 · wk 11	51	−19.0%

vs 52W High

-37.8%

$1.21 lo$2.54 hi

37.8% below 52W high, far from high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 11

1w13w26w

Week 11, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-5.3%

200 DMA: $1.67 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.98x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-19.0%

+9.0%

+3.3%

YTD

-15.5%

-3.1%

Scan Membership

Breakout Watch

Latest: 2023-11-14

3 appearances in last 60 days. First seen: 2020-06-22.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 11 · Vol 0.98x

2026-10-21S2

Wk 10 · Vol 0.85x

2026-10-20S2

Wk 10 · Vol 1.26x

2026-10-19S2

Wk 10 · Vol 0.72x

2026-10-16S2

Wk 10 · Vol 1.10x

2026-10-15S2

Wk 10 · Vol 0.70x

2026-10-14S2

Wk 9 · Vol 1.20x

2026-10-13S2

Wk 9 · Vol 1.01x

2026-10-12S2

Wk 9 · Vol 0.44x

2026-10-09S2

Wk 9 · Vol 0.62x

2026-10-08S2

Wk 9 · Vol 0.68x

2026-10-07S2

Wk 8 · Vol 0.66x

Moving averages & range

50 DMA

$2.00

200 DMA

$1.67

52W High

$2.54

52W Low

$1.21

5D Low

$1.58

Resistance levels (recent highs)

20d High

$1.94

60d High

$2.54

120d High

$2.54

250d High

$2.54

Next resistance

+22.8%

to 20d High

ROE

-133.0%

Profit margin -238.7%

Dividend Yield

0.00%

P/B 5.6

Autolus Therapeutics: quick answers

What stage is Autolus Therapeutics in?

As of Oct 22, 2026, Autolus Therapeutics (AUTL) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 12, 2026 and is in week 11. What the four stages mean

Is Autolus Therapeutics in an uptrend?

Yes. Autolus Therapeutics is in a Stage 2 uptrend. It trades 5.3% below its 200-day average, which is rising.

How far is Autolus Therapeutics from its 52-week high?

Autolus Therapeutics closed at $1.58 on Oct 22, 2026, 37.8% below its 52-week high of $2.54. Its 52-week low is $1.21.

How has Autolus Therapeutics performed over the past year?

As of Oct 22, 2026, Autolus Therapeutics is down 3.1% over the past year and down 15.5% so far in 2026.

Which sector and industry is Autolus Therapeutics in?

Autolus Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.